Outlook Therapeutics, Inc. (Nasdaq: NASDAQ:OTLK ), a pioneering biopharmaceutical company, has achieved a significant milestone in the realm of ophthalmic healthcare. With the recent issuance of a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), Outlook Therapeutics ( NASDAQ:OTLK ) inches closer...
After following the recent financing deal, OTLK shares has potential to fall up to 0.12c / share.
Additional upcoming risk of reverse split being under 1$ for considerable time.
Price is at the POC line (1yr) with increasing avg. daily volume since mid April.
OBV is displaying bullish divergence since June as it has been increasing while the price has been decreasing.
RSI is about to cross over its 13 ema.
Targeting: 2.25, 2.66
Stop 2x ATR at $1.56
Blue solid lines are established downtrends, green dotted lines are established uptrends. Both the uptrend and downtrend lines are established from equilibrium points, (not highs and lows). Thickness of lines illustrates strength of previous price action. Circles are the crossing of uptrend and downtrend (Crossfire Points), usually resulting in reactions.
Pupm&Dump trading strategy idea.
$OTLK is rising too much today.
The demand for shares of the company looks lower than the supply.
This and other conditions can cause a fall in the share price today.
So I opened a short position from $2,89;
stop-loss — $3,20;
take-profit — $2,27.
Do not view this idea as a recommendation for trading or investing. It is...
$OTLK seems to be breaking out upside on the bullish news - reported statistically significant achievement on Phase 3 trial for both Primary and Secondary endpoints!
The chart also shows the double bottom pattern completed with parallel channel formed above it, which is now being broken out upward.
Irregardless where it goes in short term, the company has...
OTLK (Outlook Therapeutics, Inc.) is expected to commercialize the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan, Greater China and other markets. The stock recently spiked up in anticipation of the most recent earnings report, and experienced a...
Bullish Pennant
Pros:
Descending volume during formation
Golden cross in blue
PPS above 50MA and 200MA
RS above 0, and ascending
ATR Ascending
R/R ratio above 8
200MA ascending, but barely
Cons:
250RSI below 50
Target:
PT = 6.05
Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $35.0 Million
announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 35,000,000 shares of common stock of Outlook Therapeutics, at a price to the public of...
BREAKOUT STOCK ALERT UPDATE
$OTLK - Outlook Therapeutics, Inc. - Common Stock (CV EM)
Initial Alert Price: $1.32
Price High: $3.62
% Gains/Losses: 174.24%
(+154.3% More Than Expected)
Potential Stop Loss: $3.439
OTLK opened in today's trading session hit $3.62 in today's session without showing any company news to justify the move. This trade unfolded over the...
BREAKOUT STOCK ALERT UPDATE
$OTLK - Outlook Therapeutics, Inc. - Common Stock (CV EM)
Initial Alert Price: $1.32
Price High: $1.65
% Gains/Losses: 25%
(+5.3% More Than Expected)
Potential Stop Loss: $1.5675
OTLK bounced back to the $1.65 Price Level into Today's Trading Session before meeting resistance and consolidating back the $1.42 to find additional support...
BREAKOUT STOCK ALERT UPDATE
$OTLK - Outlook Therapeutics, Inc. - Common Stock (CV EM)
Initial Alert Price: $1.32
Price High: $1.03
% Gains/Losses: -21.97%
(-41.7% Less Than Expected)
Potential Stop Loss: $0.9785
OTLK recently announced a $35 Million Common Stock Offering which cause the stock to drop 20% during today's pre-market session. We would stand to...
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the identification, development, manufacture, and commercialization of complex biosimilar therapeutics. It focuses on monoclonal antibodies, in the disease areas of immunology and oncology. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in...
